Aileron Therapeutics Inc ALRN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ALRN is a good fit for your portfolio.
News
-
Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
-
Aileron Therapeutics Announces CEO Transition
-
Aileron Therapeutics and Pulmonary Care Experts To Discuss the Potential Implications of LTI-03 for Idiopathic Pulmonary Fibrosis in Virtual Key Opinion Leader Event
-
Aileron Therapeutics to Host Key Opinion Leader Event on February 15, 2024
Trading Information
- Previous Close Price
- $4.25
- Day Range
- $4.51–7.42
- 52-Week Range
- $1.01–7.42
- Bid/Ask
- $5.10 / $5.15
- Market Cap
- $84.86 Mil
- Volume/Avg
- 1.8 Mil / 64,516
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Aileron Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing a novel class of therapeutics for the treatment of cancer and other diseases. The company's lead product candidate, ALRN-6924 is a novel chemoprotective medicine to treat and protect healthy cells in patients with cancer that harbors p53 mutations to reduce or eliminate chemotherapy-induced side effects. The company currently has two product candidates in clinical development, LTI-03 and LTI-01, and multiple candidates in preclinical development focused on fibrosis indications.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 15
- Website
- https://www.aileronrx.com
Valuation
|
Metric
|
ALRN
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.51 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ALRN
|
|---|---|
Quick Ratio | 7.43 |
Current Ratio | 7.88 |
Interest Coverage | — |
Quick Ratio
ALRN
Profitability
|
Metric
|
ALRN
|
|---|---|
Return on Assets (Normalized) | −39.52% |
Return on Equity (Normalized) | −106.58% |
Return on Invested Capital (Normalized) | −109.57% |
Return on Assets
ALRN
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Hkdccnvjyh | Xlydf | $553.3 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Vkbcnxfl | Pcwykk | $101.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Npzxcvwqf | Byktbq | $98.9 Bil | |
MRNA
| Moderna Inc | Wzctyrpj | Fqcd | $39.7 Bil | |
ARGX
| argenx SE ADR | Yqlpjptn | Fsdqf | $21.5 Bil | |
BNTX
| BioNTech SE ADR | Kxyjvjbk | Znry | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Zvjrnllz | Rrblbt | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Lzcdcbfy | Hlyhpwq | $17.1 Bil | |
RPRX
| Royalty Pharma PLC Class A | Mrchkfphg | Nxkvmx | $12.3 Bil | |
INCY
| Incyte Corp | Ysjrnnyd | Kfgtz | $11.8 Bil |